modelN01BX04
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Capsaicin | |
| ATC code: | N01BX04 | route: | topical |
| compartments: | 1 | |
| dosage: | 8 | mg |
| volume of distribution: | 3 | L |
| clearance: | 90 | L/h |
| other parameters in model implementation | ||
Capsaicin is a naturally occurring alkaloid found in chili peppers and is the active component responsible for their pungency. It is used topically for the relief of neuropathic and musculoskeletal pain, such as in postherpetic neuralgia and osteoarthritis. While capsaicin is effective for pain management, it is not systemically approved as an analgesic for other indications and is primarily used in topical formulations.
Pharmacokinetics
Estimated pharmacokinetic properties of capsaicin for topical administration in adults, as published data on systemic pharmacokinetics are very limited due to poor absorption and rapid metabolism. Systemic exposure following topical or dietary administration is very low.
References
Babbar, S, et al., & Bley, K (2009). Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Therapeutic drug monitoring 31(4) 502–510. DOI:10.1097/FTD.0b013e3181a8b200 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19494795
Kalliomäki, J, et al., & Simpson, DM (2013). Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy. Scandinavian journal of pain 4(2) 77–83. DOI:10.1016/j.sjpain.2012.10.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29913894
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)